Abstract: A high-strength and tough multi-component soft magnetic alloy and preparation method thereof are provided. The high-strength and tough multi-component soft magnetic alloy is composed of the following components in atomic percentage: Fe 32-45%, Co 24-29%, Ni 24-29%, Al 2.5-8%, Ti 1.5-3.5%, Ta 1.0-5%, Nb 0-2%, and Mo 0-2%. The multi-component alloys prepared by the present invention exhibit a face-centered cubic structure of the matrix, featured with high strength, high ductility, low coercivity and relatively high saturation magnetization. These properties make it suitable for manufacturing critical components for applications in industries such as electrical engineering, automatic control, mobile communications, and others.

Abstract: The present application relates to an EPA-EE nano-lipid composition and a formulation, a preparation method, and an application thereof. The EPA-EE nano-lipid composition includes a raw material having a high content of EPA-EE as a primary ingredient and includes an emulsifier containing a highly unsaturated phospholipid. The EPA-EE nano-lipid composition can be prepared into a sub-micron emulsion at nanoscale for use as an oral formulation.

Abstract: An image processing method includes obtaining a target image; splitting the target image into at least one sub-image based on a similarity of complexity in the target image; processing the at least one sub-image by at least one decoder corresponding to the at least one sub-image; and obtaining an output image based on the processed at least one sub-image. The splitting of the target image into the at least one sub image includes: splitting the target image into at least one grid of equal size; determining a similarity of complexity between adjacent grids in the at least one grid; and grouping the at least one grid into the at least one sub-image based on the similarity of the complexity between the adjacent grids.

Abstract: Various embodiments of the present disclosure provide methods and apparatuses for improved packet detection rule provision. A method performed by a first network entity comprises: transmitting packet detection information, PDI, to a second network entity, wherein the PDI indicates information on one or more traffic endpoints on which packets are to be detected.

Abstract: A solid dispersion, a preparation method therefor, and a solid formulation comprising same. The solid dispersion comprises compound A and a pharmaceutically acceptable matrix polymer, wherein the pharmaceutically acceptable matrix polymer includes an enteric high-molecular polymer and a non-enteric high-molecular polymer, and the compound A is 1-{(6-[(1-methyl)-4-pyrazolyl]-imidazo[1,2-a]pyridine)-3-sulfonyl}-6-[(1-methyl)-4-pyrazolyl]-1-hydro-pyrazolo[4,3-b]pyridine. The solid dispersion can significantly improve the solubility and dissolution stability of the compound A, prolong the supersaturation maintenance time of a drug, and further improve the bioavailability of the drug. The in vivo bioavailability of a solid formulation prepared from the solid dispersion meets the requirement of oral administration of the compound A.

Abstract: A flow cell includes a flow cell body. The flow cell body includes a frame and a fluid chamber defined in the flow cell body. The fluid chamber includes a reaction region allowing a fluid flow. A liquid inlet, a liquid outlet, and two exhaust holes connected to the fluid chamber are in the frame. Fluid into the liquid inlet flows through the reaction region in the fluid chamber and flows out through the liquid outlet. The exhaust holes discharge gas generated in the fluid chamber during the fluid flow. A flow cell with integral sealing rings and a biochemical substance reaction device are also disclosed.

Abstract: Disclosed are an application of a coronavirus SARS-CoV-2 vaccine polypeptide, a polypeptide composition and a nanoemulsion preparation thereof in the prevention of coronavirus SARS-CoV-2 wild and mutant strain infections. Specifically, provided is a coronavirus SARS-CoV-2 vaccine polypeptide having an amino acid sequence derived from an S protein of SARS-CoV-2 wild and mutant strains, the vaccine polypeptide can enable the body to generate high-level and durable humoral immune responses against SARS-CoV-2 and to produce high titers of RBD-binding antibodies and neutralizing antibodies that block the binding of RBD to ACE2. The vaccine polypeptide can be used to prevent infections of SARS-CoV-2 wild strain and B.1.1.7, B.1.351, B.1.617, B.1.1.529 and other mutant strains.

Abstract: The present invention belongs to the technical field of preparation of light metal alloy materials, in particular to a method for producing a magnesium-lithium alloy by a gaseous co-condensation method. The method comprises the steps of: 1) mixing and briquetting a lithium salt, a refractory agent and a catalyst under pressure, and then thermally decomposing to form an unsaturated composite oxide; 2) respectively crushing and ball-milling, and then briquetting the unsaturated composite oxide, magnesium oxide, a reducing agent and a fluxing agent; 3) reducing briquettes in vacuum; 4) making a gas pass through a first condensing chamber of a temperature control device, and then purifying; 5) The purified metal gas is condensed into the condensing phase of the alloy through the second condensing chamber of a quenching device; 6) obtaining the magnesium-lithium alloy with a purity being 99.5% or above by virtue of smelting and flux-refining, and then purifying by distillation.

Abstract: The present invention relates to a novel coronavirus vaccine using a TLR7 agonist conjugated peptide as an antigen and an emulsion as an adjuvant. An antigen polypeptide of the conjugated peptide is a polypeptide derived from an S protein of SARS-COV-2, and the adjuvant is an oil-in-water nanoemulsion containing squalene. The conjugated peptide nanoemulsion vaccine preparation of the present invention is thermally stable, and can induce a high level of protective humoral immune response in a cynomolgus monkey, and the neutralizing antibody titer of antiserum after immunization of cynomolgus monkey is high, such that invasion of wild-type strain and mutant novel coronavirus can be blocked. The vaccine of the present invention has a nearly complete protection effect on the upper and lower respiratory tracts of the cynomolgus monkey in a cynomolgus monkey SARS-COV-2 challenge test.

Abstract: A method for communication within a multicore system which includes a primary programmable logic device (PLD) and a secondary PLD installed respectively on a primary motherboard and a secondary motherboard includes steps of: A) by the primary PLD, determining whether the primary motherboard is connected to the secondary motherboard; B) by the primary PLD, after determining that the primary motherboard is connected to the secondary motherboard, sending a reply-requesting signal to the secondary PLD; C) by the secondary PLD, after receiving the reply-requesting signal, sending a reply signal corresponding to the reply-requesting signal to the primary PLD; D) by the primary PLD, after receiving the reply signal, sending an instruction to the secondary PLD; and E) by the secondary PLD, after receiving the instruction, performing an operation corresponding to the instruction.

Abstract: Provided is a dissolution-enhanced olaparib composition, a preparation method therefor, a use thereof, and a medicament including the dissolution-enhanced olaparib composition. The dissolution-enhanced olaparib composition includes: olaparib; copovidone and a dissolution enhancer, wherein based on 100 parts by weight of olaparib, 100 or more and less than 200 parts by weight of copovidone, and 20 to 150 parts by weight of a dissolution enhancer. The dissolution-enhanced olaparib composition and the medicament prepared therefrom have controllable stability, increased oral absorption of the active ingredient, reduced excipient dosage, improved medication convenience, and are easy for industrial production.

Abstract: Provided are a long-acting ropivacaine pharmaceutical composition, a preparation method therefor and use thereof. The pharmaceutical composition comprises: ropivacaine; a pharmaceutical solvent; a pharmaceutical phospholipid; a pharmaceutical oil; and an efficacy enhancer, an optional antioxidant and an optional acid-base regulator. The pharmaceutical composition has a controllable release behavior and a sustained release effect, can significantly reduce the peak plasma concentration of the drug, maintain a stable plasma concentration in the body, prolong the effective treatment time, reduce the effective therapeutic dose, improve the utilization of the drug, and reduce the risk of neurotoxicity. The pharmaceutical composition has a long-acting analgesic effect and can be used for pain treatment.

Abstract: A non-aqueous sustained release drug delivery system, which contains, based on the total weight of the sustained release drug delivery system, about 0.1-20% of an active agent, about 0.5-50% of a drug solvent, about 1-98% of a drug sustained release agent, about 0.1-85% of a drug solubilizer, about 0.1-10% of an efficacy enhancer, about 0-1% of an antioxidant, and about 0-8% of an acid-base regulator. The non-aqueous sustained release drug delivery system can yield an improved sustained release effect, improve bioavailability, and enhance the therapeutic effect.

Abstract: A flow cell includes a flow cell body. The flow cell body includes a frame and a fluid chamber defined in the flow cell body. The fluid chamber includes a reaction region allowing a fluid flow. A liquid inlet, a liquid outlet, and two exhaust holes connected to the fluid chamber are in the frame. Fluid into the liquid inlet flows through the reaction region in the fluid chamber and flows out through the liquid outlet. The exhaust holes discharge gas generated in the fluid chamber during the fluid flow. A flow cell with integral sealing rings and a biochemical substance reaction device are also disclosed.

Abstract: A method for preparing a high-purity metal lithium by a vacuum thermal reduction method includes the following steps: obtaining Li2O.(2-x)CaO by carrying a vacuum thermal decomposition process on a lithium-containing raw material in the presence of a refractory agent and a catalyst; mixing the obtained oxide with the fluxing agent, the catalyst and a reducing agent according to a certain ratio, and then briquetting; carrying out vacuum thermal reduction in a vacuum reduction furnace, and performing centrifugal sedimentation and micron ceramic dust removal on lithium vapor obtained by the thermal reduction to obtain a high-purity metal gas; and removing metal impurities from the gas by controlling a condensation temperature and a condensation speed of the gas so as to purify the lithium vapor, and obtaining a high-purity metal lithium with a rapid cooling technology.

Abstract: The present invention belongs to the technical field of preparation of light metal alloy materials, in particular to a method for producing a magnesium-lithium alloy by a gaseous co-condensation method. The method comprises the steps of: 1) mixing and briquetting a lithium salt, a refractory agent and a catalyst under pressure, and then thermally decomposing to form an unsaturated composite oxide; 2) respectively crushing and ball-milling, and then briquetting the unsaturated composite oxide, magnesium oxide, a reducing agent and a fluxing agent; 3) reducing briquettes in vacuum; 4) making a gas pass through a first condensing chamber of a temperature control device, and then purifying; 5) The purified metal gas is condensed into the condensing phase of the alloy through the second condensing chamber of a quenching device; 6) obtaining the magnesium-lithium alloy with a purity being 99.5% or above by virtue of smelting and flux-refining, and then purifying by distillation.

Abstract: Disclosed is an SOMCL-9112 solid dispersion. The SOMCL-9112 solid dispersion is characterized by being prepared from the following raw materials in percentage by weight: 5 percent to 60 percent of SOMCL-9112, 5 percent to 90 percent of pharmaceutically acceptable matrix polymer, 0 percent to 20 percent of surfactant, 0 percent to 20 percent of flow aid and 0 percent to 20 percent of plasticizer. Also disclosed are a preparation method of the SOMCL-9112 solid dispersion, a solid medicinal preparation containing the solid dispersion and application of the solid dispersion for preparing a medicine for treating cancer.

Abstract: The present disclosure relates to a vertical shaft impact crusher comprising a rotor having a rotor protection layer which consists of particles of objects to be crushed. The rotor includes at least: a rotor upper plate comprising a rotor upper plate hole, which is an inlet for the object for crushing which is inserted into the rotor; a rotor lower plate disposed to be separated from the lower portion of the rotor upper plate; a rotor upper plate; a rotor side wall disposed between the rotor upper plate and the rotor lower plate and coupled to the rotor upper plate and the rotor lower plate, the rotor side wall being disposed at a position spaced from the rotation center of the rotor; and a circular hole which is formed on the rotor side wall and is an outlet for the object for crushing accelerated by the rotor to come out of the rotor.

Abstract: The present disclosure discloses an omnidirectional oscillating fan with a clamp, including: a base, a mounting part being disposed on a mounting surface of the base, a main fan unit, disposed on a side of a support surface of the base, and an oscillating main control assembly, disposed between the main fan unit and the base. A cross section, perpendicular to an extending direction, of the mounting part has a circular shape. The main fan unit has a columnar shape. The oscillating main control assembly includes: a first rotational assembly, partially disposed in the mounting part, and a second rotational assembly, having one end rotatably assembled to the main fan unit and the other end fixedly assembled to a rotating end of the first rotational assembly, and being capable of rotating synchronously with the first rotational assembly.

Abstract: An olaparib oral sustained and controlled release pharmaceutical composition contains an olaparib in an improved dissolution form and a release rate adjusting matrix polymer. The pharmaceutical composition has controllable in-vivo absorption behavior, plasma concentration and PARP enzyme inhibition level, and improved drug load and/or oral absorption and/or bioavailability and/or plasma concentration control and/or enzyme inhibition level control of olaparib, and can be used as the only preparation or in combination with other therapies to treat a cancer.